{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:03:31Z","timestamp":1789967011886,"version":"4.0.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Relapse remains the most significant cause of mortality after allogeneic transplant for leukemia despite advances in understanding of disease biology and newer, targeted treatment modalities. Cure after allogeneic transplant is mediated through the graft-vs-leukemia effect, as donor immune cells recognize and reject leukemic cells, largely through recognition of mismatched HLA and\/or minor histocompatibility antigens. There is growing evidence that adjuvant but non-engrafting cellular therapies, either alone or in conjunction with conventional allogeneic transplant, improves leukemia outcomes and immune responses to such therapies have also been described during solid-organ transplants and following double cord unit transplantation, and are there associated with clinical consequences. We review these immune responses induced by third party and non-engrafting leukocytes and suggest possible mechanisms for the action of such cells. We further suggest that improved understanding of the nature of such responses might allow development of transplant technologies to make allogeneic transplants both better and safer, by targeting the immune response of the allogeneic immune system more specifically to leukemia.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1904787","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:54Z","timestamp":1789964934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Three in a bed and changing allogeneic transplant outcomes with a second, non-engrafting cell source"],"prefix":"10.3389","volume":"17","author":[{"given":"Nathan","family":"Jeffreys","sequence":"first","affiliation":[{"name":"Pediatric Blood and Marrow Transplant Programme, Royal Manchester Children\u2019s Hospital","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Poulton","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, Manchester University NHS Foundation Trust","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wynn","sequence":"additional","affiliation":[{"name":"Pediatric Blood and Marrow Transplant Programme, Royal Manchester Children\u2019s Hospital","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-333070","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia","volume":"118","author":"Leung","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01115-w","article-title":"The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer","volume":"23","author":"Schultz","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153886","article-title":"Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-5037-0_17","article-title":"Clinical development of bispecific antibodies: review, advances, and challenges in hematological Malignancies","volume":"2997","author":"Saitoh","year":"2026","journal-title":"Methods Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis","volume":"12","author":"G\u00f3mez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.10.3174","article-title":"Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","article-title":"Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation","volume":"23","author":"Rettinger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00113","article-title":"Donor selection and human leukocyte antigen loss leukemia relapse after hematopoietic cell transplantation","volume":"44","author":"Fleischhauer","year":"2026","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70303","article-title":"Donor age and type in allogeneic haematopoietic stem cell transplantation: strong effect in MDS, limited in AML","author":"Kim","year":"","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed Malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100016","article-title":"Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients","volume":"1","author":"Suryaprakash","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90165-9","article-title":"Study of factors determining the usefulness and complications of leukocyte transfusions","volume":"43","author":"Schwarzenberg","year":"1967","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb00304.x","article-title":"Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia","volume":"73","author":"Tucker","year":"1989","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0039-x","article-title":"HLA in transplantation","volume":"14","author":"Montgomery","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15233","article-title":"Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post\u2013renal transplantation","volume":"19","author":"Hassan","year":"2019","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015938","article-title":"Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation","volume":"9","author":"Wynn","year":"2025","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-718619","article-title":"CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation","volume":"128","author":"Lamers","year":"2016","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0147-0272(78)80062-2","article-title":"Blood components in the care of the cancer patient","volume":"3","author":"McCredie","year":"1978","journal-title":"Curr Probl Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.301","article-title":"A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients","volume":"27","author":"Freireich","year":"2013","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12319","article-title":"Granulocyte infusion: benefit beyond neutrophils","volume":"26","author":"Creasey","year":"2016","journal-title":"Transfus Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001737","article-title":"Cord blood CD8+ T-cell expansion following granulocyte transfusions eradicates refractory leukemia","volume":"4","author":"Hiwarkar","year":"2020","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18863","article-title":"Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8+ T-cell expansion, significant cytokine release syndrome and induction of disease remission","volume":"202","author":"Borrill","year":"2023","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02510","article-title":"Safety and clinical outcomes of pooled donor, nonengrafting expanded progenitor cells in single-unit cord blood transplantation","volume":"44","author":"Milano","year":"2026","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.05.015","article-title":"A pilot study of allogeneic cellular therapy for patients with advanced hematologic Malignancies","volume":"32","author":"Medina","year":"2008","journal-title":"Leuk Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.503","article-title":"Nonengraftment haploidentical cellular immunotherapy for refractory Malignancies: tumor responses without chimerism","volume":"15","author":"Colvin","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0281","article-title":"HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up","volume":"30","author":"Guo","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12771","article-title":"HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases","volume":"165","author":"For\u00e9s","year":"2014","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12215","article-title":"Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor\u2013primed peripheral blood stem cells infusion: a special entity of the disease","volume":"54","author":"Yuan","year":"2014","journal-title":"Transfusion (Paris)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11183","article-title":"Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia","volume":"8","author":"Jing","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-150","article-title":"Cellular immunotherapy for refractory hematological Malignancies","volume":"11","author":"Reagan","year":"2013","journal-title":"J Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.08.002","article-title":"Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment","volume":"28","author":"Krakow","year":"2014","journal-title":"Blood Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/bmt.2008.426","article-title":"CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT","volume":"43","author":"Kapp","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102662","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies","volume":"97","author":"Fuji","year":"2025","journal-title":"Curr Opin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1904787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:55Z","timestamp":1789964935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1904787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1904787"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1904787","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1904787"}}